Commercial Pipeline

Vernalis entered into a development and licensing deal with Tris Pharma, Inc, in February 2012, obtaining exclusive rights to Tris’ extended-release technology for use in the US prescription cough cold market.

In October 2015, Vernalis acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.

To see the status of these programmes at a glance – roll over any listing or click on it to find out more.